The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Annabel Samimy - Stifel, Nicolaus & Company, Inc., - Analyst
: Hi. Thanks for taking my questions. I have a few, actually. So first on CYTOGAM, what would the normalized growth rates have been for CYTOGAM
without the interruption? And what type of CYTOGAM studies do you expect will be presented? If you could just give a little clarity on that.
And then the second, I was wondering if we could dig a little deeper on the potential changes to the AAT program to accelerate it. What are some
of the changes you propose to ensure that p value and would this also hold with the EU authorities? And then while we're on that topic, I'd love
your thoughts on Sanofi's acquisition of Inhibrx and its implications for the AAT program in the market.
I'll probably get back a few after this question.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 06, 2024 / 1:30PM, KMDA.OQ - Q4 2023 Kamada Ltd Earnings Call
Question: Annabel Samimy - Stifel, Nicolaus & Company, Inc., - Analyst
: Okay. And then what type of studies are the investigators proposing and how do they plan on expanding this market or say, how do they think
that they can expand the market?
Question: Annabel Samimy - Stifel, Nicolaus & Company, Inc., - Analyst
: Okay. Great. And if we can move over to the AAT program, I guess what are some of the changes you propose to satisfy or accelerate the program?
And is that going to be accepted by the EU as well?
Question: Annabel Samimy - Stifel, Nicolaus & Company, Inc., - Analyst
: Okay. Great. And then I just want to know if you had any comments about the Sanofi acquisition of Inhibrx and their AAT program. Any thoughts
around that?
|
